Article
Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Lung cancer (Amsterdam, Netherlands) - 1 Aug 2020
Meng Pei, Koopman Bart, Kok Klaas, Ter Elst Arja, Schuuring Ed, van Kempen Léon C, Timens Wim, Hiltermann T Jeroen N, Groen Harry J M, van den Berg Anke, van der Wekken Anthonie J
Abstract excerpt
INTRODUCTION: Previous studies have reported an acquiredBRAF V600E mutation as a potential resistance mechanism to osimertinib treatment in advanced NSCLC patients with an activating mutation in EGFR. However, the therapeutic effect of combining dabrafenib and trametinib with osimertinib remains unclear. Here we report treatment efficacy in two cases with acquired BRAF V600E mutations. METHODS: Two patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.